Skip to content
Open access

A chronological framework for atherosclerosis: from environmental pressure to clinical disease, with vascular aging as a cross-cutting dimension

Oct 2026 · Frontiers in Cardiovascular Medicine · Vol 13 · 0 citations · 120 references
Medicine

TL;DR

CASCADE (Chronological Atherosclerosis Staging: Connecting Aging, Disease, and Environment), a conceptual framework that applies disease staging to atherosclerosis, is proposed as a hypothesis-generating framework, not a validated scoring system, and invites prospective evaluation of whether individuals traverse identifiable, modifiable phases of atherosclerotic disease.

Abstract

Atherosclerosis is a multiphase disease, yet contemporary cardiovascular risk stratification relies predominantly on calculators that estimate event probability within a limited pathophysiological window. Framingham, SCORE2, GLOBORISK and PREVENT capture lipid burden, metabolic parameters, and renal function, but they do not organize the chronological sequence of atherogenesis, assign measurable biomarkers to each stage, or integrate vascular aging. We propose CASCADE (Chronological Atherosclerosis Staging: Connecting Aging, Disease, and Environment), a conceptual framework that applies disease staging to atherosclerosis, organizing it into seven pathophysiological phases (F1–F7) preceded by an upstream environmental and behavioral pressure layer (F0), and spanning the trajectory from adaptive metabolic response to clinical cardiovascular disease. Each phase is mapped to a proposed dominant biomarker — from insulin resistance indices through apolipoprotein B, lipoprotein(a), and coronary artery calcium — and to a reversibility zone (largely reversible, transition, or stabilization only). Vascular aging — characterized by arterial stiffness, cellular senescence, epigenetic drift, and clonal hematopoiesis — traverses all phases as a modifiable cross-cutting dimension, with specific biological clocks applicable at each stage. The framework is developed through narrative synthesis of mechanistic, epidemiological, and clinical trial evidence, integrating current international guidelines and emerging evidence on biological aging and environmental determinants of cardiovascular risk. CASCADE complements existing risk calculators by providing chronological context for the upstream phases (F0–F3), where conventional tools offer limited guidance and the potential for disease modification is greatest. It is proposed as a hypothesis-generating framework, not a validated scoring system, and invites prospective evaluation of whether individuals traverse identifiable, modifiable phases of atherosclerotic disease — and whether integrating vascular aging measurement at each stage improves risk assessment and therapeutic decision-making.

Read PDF

Similar papers

Review Sep 2026

From Metabolic Dysfunction to Vascular Remodeling: A Multi-Indicator Framework for Subclinical Cardiovascular Disease.

Subclinical cardiovascular disease (SCVD) encompasses a spectrum of vascular abnormalities that emerge well before the onset of overt cardiovascular events. Although a wide range of metabolic, inflammatory, and vascular markers have been associated with SCVD, current assessment strategies remain largely dependent on in...

Jing Ran, Zong-Tao Chen · 0 citations
Review Open access Sep 2026

Novel blood biomarkers for heart failure mortality: mechanistic pathways, aging biology, and risk stratification

HF mortality may arise from the convergence of myocardial injury and systemic biological aging, and proteomic and metabolomic approaches are promising tools for identifying molecular phenotypes, although assay heterogeneity, insufficient age-specific validation, uncertain incremental clinical utility, and limited bedsi...

Xiao-Feng Zeng, W. Cheng, Yan Jiang et al. · 1 citation
Review Open access Oct 2026

Vascular aging biomarkers: the role of ADMA, SDMA, and inflammation

Cardiovascular risk assessment based on traditional risk factors may not fully capture subclinical vascular injury and vascular aging, supporting interest in biomarkers reflecting underlying vascular mechanisms. Endothelial dysfunction, altered methylarginine metabolism, and chronic low-grade inflammation represent int...

A. Melnitskaia, L. Machekhina, V. Pykhtina et al. · 0 citations
Review Sep 2026

Early-life atherogenesis: Mechanistic pathways, risk architecture, and clinical implications in pediatric populations.

Atherosclerosis is now recognized as a long-term biological process whose origins may be established early in life, well before the clinical expression of cardiovascular disease. The increasing prevalence of pediatric obesity, insulin resistance, sedentary behavior, and unhealthy dietary patterns has intensified intere...

Citlaly Natali de la Torre-Sosa, Rebeca López-Marure, Héctor Ochoa-Díaz-López et al. · 0 citations
Open access Oct 2026

Beyond chronological age: identifying accelerated aortic aging through laboratory indicators and geometric phenotyping

The thoracic aorta undergoes significant geometric remodeling with age, which is linked to cardiovascular diseases. However, systematic aging patterns across multiple aortic geometric phenotypes (AGPs) and the potential of routine laboratory tests to reflect aortic "accelerated aging" remain incompletely understo...

X. Duan, S.-H. Yu, Q.-Y. Hu et al. · 0 citations
Open access Oct 2026

CVMI-age quantifies multidimensional cardiovascular aging and predicts cardiovascular events: a Chinese community-based cohort study

Cardiovascular (CV) aging is a complex biological process driven by hemodynamic stress, metabolic dysregulation, and chronic inflammation. Traditional vascular aging models relying solely on arterial stiffness often fail to capture the systemic immuno-metabolic burden, leaving a gap in quantifying the residual CV...

H. Xie, F. Fan, J. Jia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.